Table 3. The risk of VOCO in the PCI group relative to the medical treatment group among lesions with qn-HRP and ql-HRP.

	Unadjusted HR (95% CI)*	p-value	Model 1 HR (95% CI)*	p-value	Model 2 HR (95% CI)†	p-value	Model 3 HR (95% CI)§	p-value
Medical treatment	Reference	NA	Reference	NA	Reference	NA	Reference	NA
PCI	0.31 (0.11-0.91)	0.033	0.26 (0.06-1.05)	0.058	0.23 (0.07-0.75)	0.015	0.25 (0.07-0.97)	0.044
This analysis was done in lesions with both qn-HRP and ql-HRP (n=138). *Model 1: adjusted for male, hyperlipidaemia, and acute coronary syndrome. †Model 2: adjusted for the use of aspirin, P2Y12 inhibitor, and statin. §Model 3: adjusted for LAD, % diameter stenosis, FFR, and LAP volume. CI: confidence interval; FFR: fractional flow reserve; HR: hazard ratio; HRP: high-risk plaque; LAD: left anterior descending artery; LAP: low-attenuation plaque; NA: not available; PCI: percutaneous coronary intervention; ql-HRP: qualitative HRP; qn-HRP: quantitative HRP; VOCO: vessel-oriented composite outcome